Table 2. Multivariate analysis of outcome after lenalidomide failure.
| Variable | Median OS | HR | 95%CI | p value |
|---|---|---|---|---|
| Age below 75y Age 75+ |
27m 18m |
1 1.64 |
[1.24 - 2.18] | 0.001 |
| Adverse K no Adverse K yes |
24m 15m |
1 1.65 |
[1.07-2.55] | 0.03 |
| RAEB no RAEB yes |
24m 18m |
1 1.41 |
[1.03 – 1.93] | 0.03 |
| SD Loss HI Intolerance PD at failure |
17m 39m 24m 11m |
1 .64 1.09 2.367 |
[0.36–1.15] [0.68–1.77] [1.609–3.481] |
.14 .73 0.01 |
| No response to LEN Response to LEN |
17m 27m |
1 1.04 |
[0.64-1.70] | 0.86 |
OS: overall survival, HR: Hazard ratio, CI: confidence interval, y: year, m: month, adverse K: adverse karyotype (per IPSS classification), RAEB: refractory anemia with excess of blasts (here limited to 5% to 10% bone marrow blasts), SD: stable disease, loss of HI: loss of hematologic improvement without bone marrow progression, PD: progressive disease at failure (to RAEB-2 or AML), LEN: lenalidomide.